title: Utility of osteopontin as a biomarker in recurrent epithelial ovarian cancer.
abstract: OBJECTIVE
  Osteopontin (OPN) is overexpressed in tumors and serum of ovarian cancer patients and may serve as a biomarker. To evaluate the utility of serum osteopontin in monitoring disease status, we evaluated 234 serum samples from post-oophorectomy patients with ovarian cancer and 38 samples from healthy controls.
  
  
  METHODS
  Serum samples were collected from 203 women with recurrent ovarian cancer and 31 newly diagnosed women participating in an experimental chemotherapeutic clinical trial. Controls included 11 young healthy women and 27 peri- or postmenopausal women without ovarian cancer. Samples were assayed for osteopontin using an enzyme-linked immunosorbent assay (ELISA) kit. Statistical analyses for group comparisons of biomarker distribution used the nonparametric Wilcoxon's rank sum test for two-group comparisons and the Kruskal-Wallis test for three-group comparisons.
  
  
  RESULTS
  Osteopontin values ranged from 25 to 1463 ng/ml for patients and 25 to 617 ng/ml for controls. Mean patient levels were lower than mean control levels (74 ng/ml vs. 147 ng/ml, respectively, P = 0.0006). Serum osteopontin levels correlated with recurrent disease versus remission (68 ng/ml vs. 34 ng/ml, P = 0.0034), presence of ascites versus absence (71 ng/ml vs. 53 ng/ml, P = 0.0002), and bulky disease vs. nonbulky disease (75 ng/ml vs. 38 ng/ml, P = 0.0005). CA-125 values yielded the same trends with greater statistical difference.
  
  
  CONCLUSIONS
  These results demonstrate that serum osteopontin concentrations in post-oophorectomy patients with recurrent ovarian cancer are not greater than in healthy controls. Nevertheless, within this heterogeneous patient population, the values do correlate with bulk of disease. The potential utility of this assay in monitoring women with CA-125 negative disease is worthy of exploration.
authors.affiliation: Division of Hematology/Oncology, Massachusetts General Hospital, Boston, MA 02114, USA.
authors.forename: K A
authors.initials: KA
authors.lastname: Brakora
authors.forename: H
authors.initials: H
authors.lastname: Lee
authors.forename: R
authors.initials: R
authors.lastname: Yusuf
authors.forename: L
authors.initials: L
authors.lastname: Sullivan
authors.forename: A
authors.initials: A
authors.lastname: Harris
authors.forename: T
authors.initials: T
authors.lastname: Colella
authors.forename: M V
authors.initials: MV
authors.lastname: Seiden
mesh_terms: D014408:Biomarkers, Tumor / Q000097:blood*; D018394:CA-125 Antigen / Q000097:blood; D017322:Clinical Trials, Phase II as Topic; D018450:Disease Progression; D004847:Epithelial Cells / Q000473:pathology; D005260:Female; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000097:blood*; D053495:Osteopontin; D010051:Ovarian Neoplasms / Q000097:blood* / Q000473:pathology / Q000601:surgery; D010052:Ovariectomy; D012795:Sialoglycoproteins / Q000097:blood*
chemical_list: D014408:Biomarkers, Tumor; D018394:CA-125 Antigen; C506895:SPP1 protein, human; D012795:Sialoglycoproteins; D053495:Osteopontin